MediPharm Labs Revolutionizes Medical Cannabis with Precision-Dosed, Non-Smokable Solutions

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) has taken a significant step forward in enhancing patient-centric cannabis solutions through a new licensing agreement with Remidose Aerosols. This partnership grants MediPharm exclusive rights to distribute advanced cannabis products, including inhalers and sublingual sprays, designed to meet the precise dosing needs of medical cannabis patients without the health risks associated with smoking.

The deal promises immediate revenue generation by transitioning current Remidose customers to MediPharm starting in August. MediPharm plans to leverage its existing GMP infrastructure and extensive customer channels to expand the reach of these products both in Canada and globally. This strategy aligns with MediPharm's commitment to providing high-quality, non-smokable cannabis solutions to a broader patient base.

Metered-Dose Inhalers: The licensed metered-dose inhalers offer patients a rapid onset of effects, akin to pharmaceutical inhalers used for conditions like asthma. This method bypasses the need for smoking or using combustible vape cartridges, which can cause respiratory issues. Patients benefit from a precise dosage with each inhalation, ensuring consistent therapeutic effects.

Pressurized Sublingual Sprays: These sprays provide an accurate and repeatable dosing experience, outperforming traditional manual pump sprays. The advanced aerosol delivery method ensures faster onset and better bioavailability, meaning the body absorbs more of the active compounds. Users also report a more pleasant taste and feel, making it a preferred choice for those who need reliable and effective cannabis therapy.

David Pidduck, CEO of MediPharm Labs, emphasized the company's dedication to non-smokable, precision-dosed cannabis formats, noting that the agreement not only brings immediate revenue but also opens numerous global medical opportunities. "We are committed to providing access to formats that are both effective and user-friendly for patients," Pidduck said. This commitment reflects a growing demand for safer and more controlled cannabis consumption methods among medical users.

Remidose CEO Michael Mayne shared his enthusiasm for the partnership, highlighting its significance in making therapeutic cannabis more accessible worldwide. "As a medical cannabis company focused on delivering smoke-free therapeutic benefits, we see this agreement as a pivotal milestone. Partnering with a trusted entity like MediPharm Labs allows us to bring our innovative products to a global audience," Mayne stated.

The collaboration between MediPharm Labs and Remidose Aerosols marks a crucial development in patient-centric cannabis care. By providing precision-dosed, non-smokable options, MediPharm is not only enhancing patient safety and convenience but also setting a new standard in medical cannabis delivery.

Would you prefer non-smokable cannabis products like inhalers and sublingual sprays for medical use?

• Yes, I prioritize my health and convenience.
• No, I prefer traditional methods.
• Maybe, I need more information about these options.